ORIC Pharmaceuticals Inc. (ORIC) Statistics & Valuation Metrics - Stocknear

ORIC Pharmaceuticals Inc.

NASDAQ: ORIC · Real-Time Price · USD
10.86
0.34 (3.23%)
At close: Sep 11, 2025, 3:59 PM
10.86
0.00%
After-hours: Sep 11, 2025, 04:10 PM EDT

ORIC Pharmaceuticals Statistics

Share Statistics

ORIC Pharmaceuticals has 97.12M shares outstanding. The number of shares has increased by 20.81% in one year.

97.12M
20.81%
19.99%
99.99%
45.7M
24
n/a

Short Selling Information

The latest short interest is 7.2M, so 7.42% of the outstanding shares have been sold short.

7.2M
7.42%
7.51%
9.33

Valuation Ratios

The PE ratio is -4.4 and the forward PE ratio is -6.65. ORIC Pharmaceuticals's PEG ratio is 0.66.

-4.4
-6.65
0
124.4
2.31
-4.94
0.66
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for ORIC Pharmaceuticals.

n/a
n/a
n/a
n/a

Financial Position

The company has a current ratio of 10.56, with a Debt / Equity ratio of 0.04.

10.56
10.56
0.04
-0.07
-0.08
0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

n/a
n/a
n/a
n/a
$-1.05M
122
0
n/a

Taxes

n/a
0%

Stock Price Statistics

The stock price has increased by 6.26% in the last 52 weeks. The beta is 1.63, so ORIC Pharmaceuticals's price volatility has been higher than the market average.

1.63
6.26%
10.42
8.56
54.11
1,014,809

Income Statement

n/a
-1.11M
-142.9M
-127.85M
-126.74M
-127.85M
-1.83
Full Income Statement

Balance Sheet

The company has 59.41M in cash and 9.36M in debt, giving a net cash position of 50.05M.

59.41M
9.36M
50.05M
-562.77M
346.86M
273.07M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -112.66M and capital expenditures -1.19M, giving a free cash flow of -113.85M.

-112.66M
-1.19M
-113.85M
-1.63
Full Cash Flow Statement

Margins

n/a
n/a
n/a
n/a
n/a
n/a
n/a

Dividends & Yields

ORIC does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
n/a
n/a
Dividend Details

Analyst Forecast

The average price target for ORIC is $17, which is 61.6% higher than the current price. The consensus rating is "Buy".

$17
61.6%
Buy
7
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
n/a
n/a

Scores

22.22
2